Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib
1. 请及时下载文件确认是否正确, 系统将在 2026-07-05 23:01:13 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.cllc.2025.12.005
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S152573042500333X
其他信息:
出版社: Elsevier BV
作者: Pascale Tomasini; Oscar Juan-Vidal; Raffaele Califano; Chien-Chung Lin; Pauline Hulo; Christophe Dooms; Jian Fang; Ana Blasco; Dariusz Kowalski; Jorge Salinas; Govind Babu; Tho Lye Mun; Alessandra Bearz; Veerle Surmont; Clarissa Baldotto; Richu Sharma; Oscar Arrieta; Katarzyna Stencel; Cynthia Card; Alona Zer; Erminia Massarelli; Bruno Fang; Sandeep Mashru; Julia Schuchard; Jan Sermon; Joris Diels; Pei-Ling Chu; Monica Withelder; Joshua M. Bauml; Sujay Shah; Mahadi Baig; Enriqueta Felip
